Picard Medical, Inc.

Picard Medical Inc. shares surged nearly 43.9% in pre-market trading after the company reported second-quarter 2026 revenue significantly ahead of Wall Street expectations. Revenue for the quarter reached approximately $2.95 million, almost twice the analyst consensus estimate of around $1.55 million. The company reported a quarterly loss of $3.05 per share, compared with analysts' expectations for a loss of approximately $1.50 per share. The exchange accepted the company's compliance plan in late July, providing investors with additional clarity over its efforts to address outstanding listing requirements. The S&P 500 was down 0.1%, while the Nasdaq declined 0.6% and the Dow was broadly unchanged.

Picard Medical, parent company of SynCardia Systems, publicly presented the integrated architecture of its next-generation Emperor Total Artificial Heart for the first time at the IEEE EMBC 2026 conference in Toronto. The poster, presented by Emperor Program Lead Taha Hasekioglu, detailed how the patent-pending Emperor Drive System integrates with the clinically proven SynCardia Total Artificial Heart ventricles, which have supported more than 2,100 patients worldwide. The Emperor Drive System is a compact electromechanical driver designed to replace the current pneumatic drivers and advance the platform toward future full implantability. The presentation also summarized preclinical evaluations showing physiologic preload-dependent output, stable performance across clinically relevant afterload ranges, and acute porcine implantation results supporting anatomic compatibility and short-duration hemodynamic stability. The SynCardia Total Artificial Heart remains the only FDA-approved, commercially available total artificial heart.

Picard Medical announced that the NYSE American has accepted its plan to regain compliance with continued listing standards. The acceptance allows the company to keep its common stock listed and trading under ticker symbol PMI while it executes operational, strategic, and financial initiatives. Picard Medical has been granted a compliance period through November 8, 2027, subject to periodic review. The company is the parent of SynCardia Systems, maker of the only FDA-approved total artificial heart.

Jet.AI announced a non-binding letter of intent for a proposed business combination with a privately held operating company in a transaction valued at approximately $320 million in enterprise value. The proposed deal would merge the existing Jet.AI entity with the unidentified operating company while retaining the NASDAQ ticker JTAI, and simultaneously spin off its data center business into an independent public company under the reserved ticker DCTR. Completion remains subject to due diligence, definitive agreements, shareholder approvals, regulatory clearances, and Nasdaq listing requirements. Separately, Xeriant received U.S. Patent No. 12,679,047 for its multilayered fire-resistant polymer composite technology used in its DUREVER materials platform and NEXBOARD construction panels. Picard Medical reported an 85% year-over-year increase in first-quarter 2026 revenue and improved gross margin to 24%, while continuing development of its Emperor artificial heart platform. Lucid attracted renewed retail investor attention following a rebound from unfounded bankruptcy rumors.

Picard Medical, parent company of SynCardia Systems, has released its pre-recorded annual stockholder presentation in advance of the 2026 Annual Meeting scheduled for July 17. The presentation highlights an 85% year-over-year revenue increase for the first three months of 2026, driven by a 116% rise in U.S. revenue, with gross margin improving to 24% from negative 4% in 2025. It also provides updates on the next-generation Emperor platform, which aims to eliminate the external pneumatic driver, with an initial configuration retaining an external controller and battery and a longer-term goal of a fully implantable system; the company plans to pursue FDA Breakthrough Device designation, continue preclinical studies, submit an Investigational Device Exemption in 2028, and begin clinical study activities in 2029. Stockholders will vote on proposals including the election of directors, amendments to the capital structure, ratification of the independent auditor, and advisory votes on executive compensation.

Picard Medical, parent company of SynCardia Systems, has released its pre-recorded annual stockholder presentation in advance of the 2026 Annual Meeting scheduled for July 17. The presentation highlights an 85% year-over-year revenue increase and improved gross margin of 28% from year-end 2025, driven by a 116% increase in U.S. revenue. It also provides an update on the next-generation Emperor platform, which aims to eliminate the external pneumatic driver, with an initial configuration retaining an external controller and battery, and a longer-term roadmap toward a fully implantable system. Development milestones include pursuit of FDA Breakthrough Device designation, a planned Investigational Device Exemption submission in 2028, and intent to begin clinical study activities in 2029. Stockholders will vote on proposals including the election of directors, amendments to the capital structure, ratification of the independent auditor, and advisory votes on executive compensation.